These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 10886203

  • 1. In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase.
    Bax BE, Bain MD, Fairbanks LD, Webster AD, Chalmers RA.
    Br J Haematol; 2000 Jun; 109(3):549-54. PubMed ID: 10886203
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA).
    Hershfield MS.
    Immunodeficiency; 1993 Jun; 4(1-4):93-7. PubMed ID: 8167743
    [No Abstract] [Full Text] [Related]

  • 5. PEGylated Recombinant Adenosine Deaminase Maintains Detoxification and Lymphocyte Counts in Patients with ADA-SCID.
    Dorsey MJ, Rubinstein A, Lehman H, Fausnight T, Wiley JM, Haddad E.
    J Clin Immunol; 2023 Jul; 43(5):951-964. PubMed ID: 36840835
    [Abstract] [Full Text] [Related]

  • 6. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
    Hershfield MS, Chaffee S, Sorensen RU.
    Pediatr Res; 1993 Jan; 33(1 Suppl):S42-7; discussion S47-8. PubMed ID: 8433874
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase.
    Chun JD, Lee N, Kobayashi RH, Chaffee S, Hershfield MS, Stiehm ER.
    Ann Allergy; 1993 Jun; 70(6):462-6. PubMed ID: 8507039
    [Abstract] [Full Text] [Related]

  • 12. A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient.
    Tartibi HM, Hershfield MS, Bahna SL.
    Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26684479
    [Abstract] [Full Text] [Related]

  • 13. [Polyethylene glycol-adenosine deaminase: a new adenosine deaminase deficiency therapy. Value of deoxyadenosine triphosphate determination for therapeutic monitoring].
    Bory C, Boulieu R, Souillet G, Hershfield MS.
    Therapie; 1991 Jan; 46(4):323-6. PubMed ID: 1948809
    [Abstract] [Full Text] [Related]

  • 14. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase.
    Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL.
    N Engl J Med; 1987 Mar 05; 316(10):589-96. PubMed ID: 3807953
    [Abstract] [Full Text] [Related]

  • 15. Molecular basis for paradoxical carriers of adenosine deaminase (ADA) deficiency that show extremely low levels of ADA activity in peripheral blood cells without immunodeficiency.
    Ariga T, Oda N, Sanstisteban I, Arredondo-Vega FX, Shioda M, Ueno H, Terada K, Kobayashi K, Hershfield MS, Sakiyama Y.
    J Immunol; 2001 Feb 01; 166(3):1698-702. PubMed ID: 11160213
    [Abstract] [Full Text] [Related]

  • 16. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
    Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, Parkman R, Weinberg K, Kohn DB.
    Clin Immunol; 2005 Nov 01; 117(2):133-43. PubMed ID: 16112907
    [Abstract] [Full Text] [Related]

  • 17. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
    Weinberg K, Hershfield MS, Bastian J, Kohn D, Sender L, Parkman R, Lenarsky C.
    J Clin Invest; 1993 Aug 01; 92(2):596-602. PubMed ID: 8349799
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open-label, single-arm, phase 3, and postmarketing clinical study.
    Onodera M, Uchiyama T, Ariga T, Yamada M, Miyamura T, Arizono H, Morio T.
    Immun Inflamm Dis; 2023 Jul 01; 11(7):e917. PubMed ID: 37506145
    [Abstract] [Full Text] [Related]

  • 19. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase.
    Husain M, Grunebaum E, Naqvi A, Atkinson A, Ngan BY, Aiuti A, Roifman CM.
    J Pediatr; 2007 Jul 01; 151(1):93-5. PubMed ID: 17586199
    [Abstract] [Full Text] [Related]

  • 20. Polyethylene glycol-modified adenosine deaminase improved lung disease but not liver disease in partial adenosine deaminase deficiency.
    Somech R, Lai YH, Grunebaum E, Le Saux N, Cutz E, Roifman CM.
    J Allergy Clin Immunol; 2009 Oct 01; 124(4):848-50. PubMed ID: 19665771
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.